GIANNATEMPO, PATRIZIA
 Distribuzione geografica
Continente #
EU - Europa 943
NA - Nord America 526
AS - Asia 160
SA - Sud America 5
Totale 1.634
Nazione #
US - Stati Uniti d'America 521
DE - Germania 503
GB - Regno Unito 213
IT - Italia 80
CN - Cina 67
SE - Svezia 62
SG - Singapore 45
IE - Irlanda 21
FI - Finlandia 13
KR - Corea 13
IN - India 11
FR - Francia 10
RU - Federazione Russa 10
HK - Hong Kong 8
BE - Belgio 7
JP - Giappone 5
TR - Turchia 5
UA - Ucraina 5
CA - Canada 4
NL - Olanda 4
BR - Brasile 3
DK - Danimarca 3
AT - Austria 2
CZ - Repubblica Ceca 2
GR - Grecia 2
ID - Indonesia 2
NO - Norvegia 2
PL - Polonia 2
PT - Portogallo 2
VN - Vietnam 2
AR - Argentina 1
EC - Ecuador 1
IL - Israele 1
MX - Messico 1
MY - Malesia 1
Totale 1.634
Città #
Frankfurt am Main 474
Chandler 182
Southend 179
Seattle 34
Princeton 30
Wilmington 27
Fairfield 25
Milan 25
Singapore 24
Dublin 21
Ann Arbor 20
Munich 18
Phoenix 13
Des Moines 12
Houston 11
Nanjing 11
Ashburn 10
Beijing 10
Falls Church 10
Woodbridge 10
Bengaluru 7
Brussels 7
Cambridge 7
Hong Kong 7
Jinan 7
Redwood City 6
San Diego 6
Boardman 5
Eitensheim 5
New York 5
Kent 4
Shenyang 4
Tokyo 4
Amsterdam 3
Aprilia 3
Changsha 3
Chicago 3
Lessolo 3
London 3
Los Angeles 3
Piacenza 3
Seoul 3
Toronto 3
Ancona 2
Angri 2
Brno 2
Buffalo 2
Chengdu 2
Diyarbakir 2
Florence 2
Formia 2
Haikou 2
Hangzhou 2
Hanoi 2
Hefei 2
Helsinki 2
Ipswich 2
Jiaxing 2
Kunming 2
Molteno 2
Mountain View 2
Mumbai 2
Rome 2
Taranto 2
Almere Stad 1
Andover 1
Athens 1
Baltimore 1
Berlin 1
Bitonto 1
Brugine 1
Central District 1
Cleveland 1
Concesio 1
Düsseldorf 1
Freitas 1
Fremont 1
Fuzhou 1
Haifa 1
Hebei 1
Huntington 1
Hyderabad 1
Jakarta 1
Kuala Lumpur 1
Medford 1
Novara 1
Oslo 1
Ottawa 1
Polska 1
Puebla City 1
Quito 1
Salem 1
San Francisco 1
Santa Clara 1
Silver Spring 1
Taiyuan 1
Takamatsu 1
Thessaloníki 1
Tianjin 1
Venezia 1
Totale 1.328
Nome #
Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006)) 206
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma 149
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation 142
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma 140
Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma. 130
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy 126
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer 124
Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica 111
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 101
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma : a systematic review and meta-analysis of patient outcomes 93
Biomarker-driven immunotherapy for precision medicine in prostate cancer 93
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes 88
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment 82
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer : an open label, single-group, phase 2 trial 76
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer 75
Totale 1.736
Categoria #
all - tutte 4.805
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.805


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202085 0 0 0 7 2 4 7 9 26 18 7 5
2020/2021138 47 8 6 4 22 10 9 14 9 4 1 4
2021/2022203 6 5 8 7 12 16 7 6 10 20 24 82
2022/2023347 45 55 38 54 13 48 7 20 54 2 8 3
2023/2024428 8 6 8 6 42 7 65 60 27 64 67 68
2024/2025187 62 55 52 18 0 0 0 0 0 0 0 0
Totale 1.736